DrugPatentWatch Database Preview
Profile for Australia Patent: 2008228714
» See Plans and Pricing
US Patent Family Members and Approved Drugs for Australia Patent: 2008228714
US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
---|---|---|---|---|
Start Trial | Aug 19, 2028 | Astrazeneca Ab | FARXIGA | dapagliflozin |
Start Trial | Mar 21, 2028 | Astrazeneca Ab | FARXIGA | dapagliflozin |
Start Trial | Mar 21, 2028 | Astrazeneca Ab | QTERN | dapagliflozin; saxagliptin hydrochloride |
Start Trial | Mar 21, 2028 | Astrazeneca Ab | BYDUREON | exenatide synthetic |
Start Trial | Mar 21, 2028 | Astrazeneca Ab | BYDUREON PEN | exenatide synthetic |
Start Trial | Mar 21, 2028 | Astrazeneca Ab | BYDUREON BCISE | exenatide |
>US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |